您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > CG-200745
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CG-200745
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CG-200745图片
CAS NO:936221-33-9
规格:98%
分子量:427.54
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
CG-200745 是一种新型有效的HDAC 抑制剂,对于敏感的非小细胞肺癌 (NSCLC) 细胞系的IC50s< 3 μM。 CG-200745 诱导 p53 的积累,促进 p53 依赖性反式激活,并增强 p53 靶基因,MDM2 和 p21 (Waf1/Cip1) 编码的蛋白质在人前列腺癌细胞中的表达。 CG-200745 减弱了单侧输尿管梗阻 (UUO) 小鼠肾中 p38 MAPK 的磷酸化,并通过抑制肾纤维化和炎症而具有肾脏保护作用。
CAS:936221-33-9
分子式:C24H33N3O4
分子量:427.54
纯度:98%
存储:Store at -20°C

Background:

CG-200745 is a potent HDAC inhibitor, with IC50s of<3 μM for sensitive non-small cell lung cancer (NSCLC) cell lines. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of proteins encoded by p53 target genes, MDM2 and p21 (Waf1/Cip1) in human prostate cancer cells[1]. CG-200745 attenuates phosphorylation of p38 MAPK in kidneys and it has a renoprotective effect by suppressing renal fibrosis and inflammation in a unilateral ureteral obstruction (UUO) mouse model[2]. HDAC p38 MAP kinase p53


CG-200745 (0-10 μM; 48 hours) reduces the Calu6 cells proliferation to 40% of untreated cells[1]. CG-200745 (3 μM; 1-24 hours) significantly increases Calu6 cells proportion in G2/M phase (69%)[1]. CG-200745 (0-10 μM; 1-24 hours) treatment with low concentration significantly increases the acetylation of histone H3 and H4 in Calu6 cells at various sites in a time-dependent manner up to 24 hours after treatment[1]. Cell Proliferation Assay[1] Cell Line: Calu6 cells


CG-200745 (p.o.; 30 mg/kg/day; for 7 days) attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys[2]. Animal Model: Male 8-week-old C57BL/6 J mice weighing 20